Navigation Links
Beckman Coulter Elects AMN Healthcare Executive to Board of Directors

FULLERTON, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer of products that simplify and automate complex biomedical testing, announced today that Susan R. Nowakowski, chief executive officer, president, and director of AMN Healthcare Services, Inc. (NYSE: AHS) has been elected to the board of directors of Beckman Coulter, effective December 10.

(Logo: )

"Susan is a highly respected business leader with experience in healthcare services, life sciences and venture capital. She has an outstanding record of accomplishments and delivering value for AMN Healthcare shareholders," said Betty Woods, chairman of the Beckman Coulter board of directors. "Her strong leadership, operational and financial skills will be of great value to our board."

Since 2005, Nowakowski has served as CEO of AMN Healthcare Services, the largest healthcare staffing company in the U.S. and the first to exceed $1 billion in annual revenue. Nowakowski has been employed at AMN, in a variety of leadership roles including chief financial officer and chief operating officer, since 1990. Prior to that, she worked at BioVest Partners, a venture capital firm, and at Hybritech, a subsidiary of Eli Lilly that Beckman Coulter later acquired.

Nowakowski also serves on the board of directors of the University of California San Diego Sulpizio Family Cardiovascular Center and San Diego State University College of Business Administration. She served on the board of Playtex Products, Inc. from 2001 until they were sold to Energizer Holdings in October 2007 and was chair of the audit committee. In 2003, she was recognized as one of the "Top Women Who Mean Business" by the San Diego Business Journal.

About Beckman Coulter, Inc.

Based in Fullerton, California, Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue consisting of supplies, test kits, service and operating-type lease payments represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion. For more information, visit

Contacts: Mary Luthy, Beckman Coulter Robert Raynor, Beckman Coulter
Corporate Communications Investor Relations

(714) 773-7964 (714) 773-7620

SOURCE Beckman Coulter, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
9. KGI Elects Three New Members to Board of Trustees
10. The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors
11. Genaera Elects New Board Member and Announces Executive Appointments
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):